Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Sarcoma 3Gastrointestinal 3Endocrine 3NET 2Genitourinary 2Other solid neoplasm 1

Conditions

Prostatic Neoplasms 1425Carcinoma, Renal Cell 586Urinary Bladder Neoplasms 368Kidney Neoplasms 257Carcinoma, Transitional Cell 190Neoplasm Metastasis 163Neoplasms 123Melanoma 83Breast Neoplasms 80Carcinoma, Non-Small-Cell Lung 77Testicular Neoplasms 67Ovarian Neoplasms 62Sarcoma 55Urethral Neoplasms 51Non-Muscle Invasive Bladder Neoplasms 50Wilms Tumor 49Lung Neoplasms 45Colorectal Neoplasms 43Neuroblastoma 39Uterine Cervical Neoplasms 38Penile Neoplasms 37Pancreatic Neoplasms 37Urologic Neoplasms 34Recurrence 32Lymphoma, Non-Hodgkin 32Ureteral Neoplasms 28Osteosarcoma 28Testicular Germ Cell Tumor 26Head and Neck Neoplasms 26Clear-cell metastatic renal cell carcinoma 26

Interventions

cixutumumab 1Temozolomide 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neuroectodermal Tumors × Genitourinary × Clear all
NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Washington University School of Medicine

Phase 2 Withdrawn
CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡